Zur Problematik der Spätrezidive von Hodentumoren Roya NabaviMeinem Mann1.1.1.11.2.21.3.34561.4.71.5.89102.2.1.10112.2.2.2.1.122.2.2.2.3.13142.4.152.5.163.3.1.163.1.1.173.1.2.3.2.3.2.1.18493#273493#2903.2.2.19203.2.3.3.2.4.213.3.3.3.1.2223557#4173.3.2.243.3.3.25263.4.3.4.1.3.4.2.3.4.3.273.4.4.28293.4.5.303.4.6.313.4.7.323.4.8.333.5.3435363738394041424344454647484950514.515253545556575859606162636465666768697071725.727374756.7576777879808182605#52283AbkürzungsverzeichnisLiteraturlisteDanksagungLebenslaufEidesstattliche ErklärungdeInhaltsverzeichnisHilfe Literaturliste 1. Bamberg M, Schmoll HJ, Weißbach L, et al. Interdisziplinäre Konsensus-Konferenz zur Diagnostik und Therapie von Hodentumoren. Strahlenther Onkol 1997; 173: 397-406 2. Schmoll HJ, Bamberg M, Weißbach L. Interdisziplinäre Konsensus-Konferenz zur Diagnostik und Therapie von Hodentumoren. Onkologie 1997; 20: 164-170 3. Krege S, Schmoll HJ, Souchon R, Interdisciplinary Consensus on diagnosis and treatment of testicular germ cell tumors: result of an update conference on evidence-based medicine (EBM). Eur Urol 2001; 40: 372-391 4. Leitlinie zur Diagnostik und Therapie von Hodentumoren auf Grundlage evidenzbasierte Medizin für die German Testicular Cancer Study Group, im Auftrag der Deutschen Krebsgesellschaft (Souchon R, Schmoll HJ, Krege S, Hrsg) Zuckschwerdt Verlag
München Bern Wien New York
(2002) 5. Mostofi FK, Sobin LH, Histological typing of testis tumors, International Classification of Tumors, No. 16 WHO,
Genf
(1977) 6. Testikuläre Keimzelltumoren: Histologie, Klassifikation, Pathologie und Häufigkeit. (Weißbach L, Hildebrand G, Hrsg) Zuckschwerdt Verlag
München
(1982) 7. UICC. TNM-Klassifikation maligner Tumoren. (Wittekind C, Wagner G, Hrsg), 5. Aufl.
Berlin Heidelberg New York:
Springer, 1997 8. Cavalli F, Monfardini S, Pizzocaro G, Report on the International Workshop on Staging and Treatment of Testicular Cancer. Eur J Cancer 1980 ; 16: 1367-1372 9. Einhorn LH: Testicular cancer as a model for a curable neoplasm: The Richard and Hilda Rosenthal Foundation Award Lecture. Cancer Res 41: 3275-3280, 1981 10. Böhlen D, Borner M, Sonntag RW, et al. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 1999; 161: 1148-1152. 11. Horwich A, Alsanjari N, A’Hearn R, et al. Surveillance following orchiectomy for stage I testicular seminoma. Br J Cancer 1992; 65: 775-778. 12. Fernandez EB, Moul JW, Foley JP, et al. Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. Urology 1994; 44: 548-552. 13. Donohue JP, Thornhill JA, Foster RS, et al. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 1993; 149: 237-243. 14. Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J clin Oncol 1992; 10: 1762-1768. 15. Bamberg M, Schmidberger H, Meisner C, et al. Radiotherapy for stage I and IIA/B testicular seminoma Int J Cancer 1999; 83: 823-827. 16. Weißbach L, Bussar-Maatz R, Flechtner H, et al. PRLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol 2000; 37: 582-594. 17. Maed GM, International consensus prognostic classification for metastatic germ cell tumors treated with platinum based chemotherapy: Final report of the international Germ Cell Cancer Collaborative Group (IGCCCG). Proc Am Soc Clin Oncol 1995; 14: 235 abstract 615. 18. Sonneveld D, Hoekstra HJ, van der Graaf WTA, et al. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 2001; 91: 1304-1315. 19. Warde P, Gospodarowicz MK, Banerjee D, et al. Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol 1997; 157: 1705-1710. 20. Warde P, von der Maase H, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance. Proc Am Soc Clin Oncol 1998; 17: 309 a. abstract 1188 21. Heidenreich A, Sesterhenn IA, Mostofi FK, et al. Prognostic factors that identify patient with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 1998; 83: 1002-1011. 22. International Germ Cell Cancer Collaborative Group (IGCCCG). The international germ cell consensus classification: A Prognostic Factor-Based Staging System for Metastatic Germ Cell Cancer. J Clin Oncol 1997; 15: 594-603. 23. Melchior D, Bockemeyer C, Schüller H, Bock C, Müller SC, Albers P. Late Relapse in Testis Cancer. Aktuell Urol 2002; 33: 455-462. 24. Nühnen H, Bussar-Maatz R, Weißbach L, et al. Nachsorge bei Hodentumoren- 2 Jahre oder länger? 1. Jahrestagung Berliner Urologischen Gesellschaft, 1994. 25. Peckham MJ, Brada M. Surveillance following orchidectomy for Stage I testicular cancer. Int J Androl 1987; 10: 247-254 26. Pizzocaro G, Zanoni F, Salvioni R, Milani A, Piva L, Pilotti S. Difficulties of a surveillance study omitting retroperitoneal lymphadenectomy in clinical stage I nonseminomatous germ cell tumors of the testis. J Urol 1987 ; 138 : 1393-1396 27. Nicols C, Baniel J, Foster R, Donohue JP, Lawrnce H, et al, Proceedings of ASCO 1994; 13: 234 28. Warde PR, Gospodarowicz MK, Goodmann PJ, et al. Results of a policy of surveillance in stage I testicular seminoma. Int J Radiat Oncol Biol Phys 1993; 27: 11-15 29. von der Maase H, Specht L, Jacobsen GK, et al. Surveillance following orchidectomy for stage I seminoma of the testis, Eur J Cancer 1993; 29A: 1931-1934 30. Ondrus D, Matoska J, Belan V, et al. Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment. Eur Urol 1998; 33: 562-566. 31. E. F. Codd, The Relational Model for Database Management - Version 2, Addison-Wesley 1990 32. Donohue JP, Thornhill JA, Foster RS, et al. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: The Indiana University experience (1965 to1989). J Urol 1995; 153: 85-89. 33. Kennedy BJ, Torkelson JL, Fraley EE. Adjuvant chemotherapy for stage II nonseminomatous germ cell cancer of the testis. Cancer 1994; 73: 1485-1489. 34. Kuczyk M, Machtens S, Stief C, et al. Management of the post-chemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumors (GCT). Int J Cancer 1999; 83: 852-855. 35. Albers P, Dommer K, Müller SC. Testicular tumors. Mortality and recurrence after inadequate therapy. Urologe A 1998; 37: 625-628. 36. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH. Late relapse of testicular cancer. J Clin Oncol 1995; 13: 1170-1176. 37. Borge N, Fossa D, Ous S, Stenwig AE, Lien HH. Late recurrence of testicular cancer. J Clin Oncol 1988; 6: 1248-1253. 38. Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 1997; 8: 41-47. 39. George DW, Foster RS, Hromas RA, et al. Update on late relapse of germ cell tumor: A clinical and Molecular Analysis. J Clin Oncol 2003; 21: 113-122. 40. Shahidi M, Normann AR, Dearnaley DP, Nicolls J, Horwich A, Huddart RA. Late recurrence in 1263 men with testicular germ cell tumors: multivariate analysis of risk factors and implications for management. Cancer 2002; 95: 520-530. 41. Baniel J, Roth BJ, Foster RS, Donohue JP. Cost and risk benefit in the management of clinical stage II nonseminomatous testicular tumors. Cancer 1995; 75: 2897-2903. 42. Baniel J, Roth BJ, Foster RS, Donohue JP. Cost and risk benefit considerations in the management of clinical stage I nonseminomatous testicular tumors. Ann Surg Oncol 1996; 3: 86-93. 43. Deleo MJ, Greco FA, Hainsworth JD, Johnson DH. Late recurrence in long-term-survivors of germ cell neoplasms. Cancer 1988; 62: 985-988 44. Strohmeyer T, Buszello H. Late metastases in seminoma: incidence, localization, and therapeutic implications. Urology 1992; 6: 515-518 45. Ravi R, Oliver RT, Ong J, Badenoch DF, Fowler CG, Paris AM, Hendry WF. A single-centre observational study of surgery and late malignant events after chemotherapy for germ cell cancer. B J Urol 1997; 80: 647-652. 46. Levi JA, Thomson D, Sandeman T, Tattersall M, Raghavan D, Byrne M, Gill G, Harvey V, Burns I, Snyder R. A prospective study of cisplatin-based combination chemotherapy in advanced germ cell malignancy: role of maintenance and long-term follow-up. J Clin Oncol 1988; 6: 1154-1160. 47. Weißbach L, Hartlapp JH. Adjuvant chemotherapy of metastatic stage II nonseminomatous testis tumor. J Urol 1991; 146: 1295-1298 48. Strickland P., Seminoma testis with metastases after 31 years, Br Med J 1965; 349 49. Dieckmann KP, Boeckmann W, Brosig W, Jonas D, Bauer HW. 34. Tagung der Nordrhein-Westfälischen Gesellschaft für Urologie, Abstract 5 1988. 50. Erpenbach K, Derschum W, Reis M, Vietsch v. H. Ergebnisse einer engmaschigen Tumornachsorge. Urol. A 1990; 29: 102-107. 51. Baumann G, Venkatesan V, Ago C, Radwan J, Dar A, Winquist E. Postoperative radiotherapy for stage I/II seminoma: results for 212 patients. Int J Radiat Oncol Biol Phys. 1998; 27: 11-15 52. Sagalowsky AI, Mc Connell JD, Admire R. Uncommon sites of recurrent seminoma and implications for therapy. Cancer 1986; 57: 1060 53. Carl J, Christensen TB, von der Maase H. Cisplatinum dose dependent response in germ cell cancer evaluated by tumor marker modelling. Acta Oncol 1992; 31: 749-753 54. Sonneveld D, Sleijfer D, Koops H, Keemers-Geld M, Molenaar W, Hoekstra H. Mature Teratoma Identified after Postchemotherapy Surgery in Patients with Disseminated Nonseminomatous Testicular Germ Cell Tumors. Cancer 1998; 82: 1343-1351 55. Baniel J, Foster RS, Einhorn LH, Donohue JP. Late relapse of clinical stage I testicular cancer. J Urol 1995; 154: 1370-1372. 56. Schrader A, Heidenreich A, Ohlmann CH, Rosmanith S. Ändern evidenz-basierte Leitlinien klinikinterne individuelle Therapieentscheidungen bei Patienten mit Keimzelltumoren? DGU 2003 Abstract V 9.6 57. Hendry WF, Norman AR, Dearnaley DP, Fisher C, Nicolls J, Huddart RA, Horwich A. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 2002; 94: 1668-1676. 58. Hartmann JT, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C. Postchemotherapy resections of residual masses form metastatic nonseminomatous testicular germ cell tumors. Ann Oncol 1997; 8: 531-538 59. Steyerberg EW, Keizer HJ, Stoter G, Habbema JD. Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections. Eur J Cancer 1994; 9: 1231-1239 60. Sheinfeld J. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies. Semin Urol Oncol. 2002; 20: 262-271. 61. Albers P, Weinknecht S, Krege S, Kliesch S, Hartmann M, Heidenreich A, Walz P, Fimmers R. Prediction of necrosis after chemotherapy of advanced germ-cell-tumors-Results of a prospective multicenter trial of the GTCSG. J Urol 2002; 167: Abstract 690: 172 62. Gholam D, Fizazi K, Terrier-Lacombe MJ, Jan P, Culine S, Theodore C. Advanced Seminoma-Treatment Results and Prognostic Factors for Survival After First.Line, Cisplatin-Based Chemotherapy and for Patients with Recurrent Disease. A Singel-Institution Experience in 145 Patients. Cancer 2003; 98: 745-752 63. Warde P, Gospodarowicz MK, Panzarella T, et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 1995; 13: 2255-2262 64. Fossa SD, Aass N, Kaalhus O. Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 1989; 16: 383-388 65. Patel MI, Motzer RJ, Sheinfeld J. Management of recurrence and follow-up strategies for patients with seminoma and selected high-risk groups. Urol Clin N Am 2003; 30: 803-817 66. Rabbani F, Sheinfeld J, Farivar-Mohseni H, Leon A, Rentzepis MJ, Reuter VE, et al. Low-Volume Nodal Metastases Detected at Retroperitoneal Lymphadenectomy for Testicular Cancer: Pattern and Prognostic Factors for Relapse. J of Clin Oncol 2001; 19: 2020-2025 67. Schölermann KH, Dettmann R, Hartmann M. Die risikogesteuerte Hodentumornachsorge. Urologe A 1996; 35: 326-330 68. Mead GM, Stenning SP, Parkinson MC, Horwich A, Fossa SD, Wilkinson PM, Kaye SB, Newlands ES, Cook PA. The Second Medical Research Council Study of Prognostic Factors in Nonseminomatous Germ Cell Tumors. J Clin Oncol 1992; 10: 85-94 69. Collette L, Sylvester RJ, Stenning SP, Fossa SD, Mead GM, de Wit R, de Mulder PHM, Neymark N, Lallemand E, Kaye SB. Impact of the Treating Institution on Survival of Patients With “Poor-Prognosis” Metastatic Nonseminoma. Journal of the National Cancer Institute 1999; 91: 839-846 70. Pohar KS, Rabbani F, Bosl GJ, Motzer RJ, Bajorin D, Sheinfeld J. Results of retroperitoneal lymph nod dissection for clinical stage I and II pure embryonal carcinoma of the testis. Journal of Urologie 2003; 170: 1155-1158 71. Moul JW, McCarthy WF, Fernandez EB, Sesterhenn IA. Percentage of embryonal carcinoma and vascular invasion predicts pathologic stage in clinical stage I nonseminomatous testicular cancer. Cancer Res 1994; 54: 1-3 72. Simmonds PD, Lee AHS, Theaker JM, et al: Primary pure teratoma of testis. J Urol 1996; 155: 939-942 73. Weißbach L, Böttcher K, Sommerhof C. Kindlichen Hodentumoren aus klinischer Sicht. In Weißbach L, Hildebrand G. (Hrsg.): Register und Verbundstudie für Hodentumoren – Bonn. Ergebnisse einer prospektiven Untersuchung. Zuckschwerdt,
München
1982; 215-264 74. Ebert W, Böhm E, Walz PH. Das maligne Potential des reifen Hodenteratoms. Akt. Urol 1992; 23: 113-117 75. Heidenreich A, Neubauer S, Mostofi FK, Sesterhenn IA, Moul JW, Engelmann UH. Das reife Teratom des Hodens im klinischen Stadium I – retroperitoneale Lymphadenektomie oder Surveillance? Urologe A 1997; 36: 440 – 444 76. Rabbani F, Farivar-Mohseni H, Leon A, Motzer RJ, Bosl GJ, Sheinfeld J. Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma. Urology 2003; 62: 1092 – 1096 77. Rabbani F, Gleave ME, Coppin CM, Murray N, Sullivan LD. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. Cancer 1996; 78: 480 78. Birch R, Williams S, Cone A, Einhorn L, Roark P, Turner S, Greco FA. Prognostic Factors for Favorable Outcome in Disseminated Germ Cell Tumors. Journal of Oncology 1986; 4: 400-407 79. E. F. Codd, A Relational Model for Large Shared Data Banks, Comm. ACM, 13, June 1970 80. Javadpour N, Canning DA, O’Connell KJ, et al. Predictors of recurrent clinical stage I nonseminomatous testicular cancer. A prospective clinicopathologic study. Urology 1986; 27: 508-11 81. Lipphardt ME, Albers P. Late relapse of testicular cancer. Wold J. Urol. 2004; 22: 47- 54

Direkt oder sinngemäß zitiert worden